小分子对炎症性肠病和感染和恶性瘤的风险:系统性审查和元分析
LiXue Chen1, Chang Su1, Hao Ding1
1Department of Gastroenterology, the First Affiliated Hospital of Anhui Medical University, He Fei 230022, China.
小分子药物,特别是JAK抑制剂,增加了炎症性肠病 (IBD) 患者的感染风险. 对于这些治疗方法来说,长期安全监测至关重要.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD) 管理通常涉及小分子药物.
- 雅克抑制剂和S1P受体调节剂是关键的治疗类.
- 评估感染和恶性瘤风险的安全概况至关重要.
研究的目的:
- 评估成年IBD患者感染和恶性瘤的风险,这些患者接受小分子药物治疗.
- 为了比较JAK抑制剂和S1P受体调节剂在IBD中的安全性.
主要方法:
- 来自14项研究的27项随机对照试验 (RCT) 的元分析.
- 包括10,623名成年IBD患者.
- 分析了与JAK抑制剂和S1P受体调节器相关的感染和恶性瘤数据.
主要成果:
- 小分子药物,特别是JAK抑制剂,显著增加任何感染 (RR: 1.23) 和疹 (RR: 2.23) 的风险.
- 特定的JAK抑制剂如菲尔戈提尼布,托法西提尼布和乌帕达西提尼布与UC和CD患者的感染风险增加有关.
- 在使用S1P受体调节器时,没有观察到感染或恶性瘤的风险增加.
结论:
- 在一年的随访期内,JAK抑制剂与IBD患者感染和疹菌的风险增加有关.
- 在IBD中使用JAK抑制剂的长期安全性需要持续监测.
- S1P受体调节器没有显示出感染或恶性瘤的风险增加.
更多相关视频
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
07:05Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation
Published on: December 15, 2017
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
